Status:
COMPLETED
Impact of High-level Oxygen Therapy on the Reconditioning of Type I Hypoxemic Respiratory Insufficiency Patients in Intensive Care
Lead Sponsor:
Dr David DE BELS
Conditions:
Hypoxemic Respiratory Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
High-throughput oxygen therapy is known as an alternative to non-invasive ventilation, with a benefit in terms of survival in non-hypercapnic respiratory failure patients. The use of high-throughput ...
Eligibility Criteria
Inclusion
- Acute respiratory insufficiency type I, oxygen partial pressure (PaO2) \<60 mmHg under oxygen without hypercapnia.
- Invasive arterial pressure measure
Exclusion
- Hemodynamic instability
- Patient under continuous high throughput oxygen therapy
- Left cardiac insufficiency
- Arteritis of the lower limbs
- Neuromuscular pathology
- Osteo-articular limitations
- Hemoglobin inferior to 8g/dl
Key Trial Info
Start Date :
August 18 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04022603
Start Date
August 18 2017
End Date
August 3 2020
Last Update
March 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020